Skip to main content
. 2019 May 2;105(2):414–423. doi: 10.3324/haematol.2019.216168

Figure 2.

Figure 2.

Relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS) and overall survival (OS) by cytogenetic groups. The 2-year cumulative incidence of relapse increased significantly from the “none group” up to the “abn(17p) group”, reaching 45.3% [95% CI: 29.9-59.5], 52.7% [95% CI: 40.9-63.1], 61.5% [95% CI: 53.5-68.6] and 65.7% [95% CI: 58.1-72.3] in the none, CK, MK and abn(17p) groups, respectively (P=0.006) (A). The 2-year probability of NRM was similar across the four groups, reaching 19.9% [95% CI: 16.4-23.7] (P=0.86) (B). The 2-year probability of LFS was 39.4% [95% CI: 24.8-54] for the “none group”, 25.4% [95% CI: 15.6-35.3] for the “CK group”, 19.8% [95% CI: 13.5-26.1] for the “MK group” and 12.6% [95% CI: 7.5-17.7] for the “abn(17p) group” (P<0.001) (C). The 2-year probability of OS decreased significantly from the “none group” down to the “abn(17p) group”, reaching 59.7% [95% CI: 45.2-74.2], 31% [95% CI: 20.5-41.6], 26.5% [95% CI: 19.4-33.5] and 16.3% [95% CI: 10.5-22] in each group respectively (P<0.001) (D).